Cargando…

Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma

Immunotherapy with anti-PD-1 antibody preliminarily showed promising efficacy for treating esophageal squamous cell carcinoma (ESCC). Herein, we used tissue microarrays and immunohistochemically analyzed PD-L1 and various tumor infiltrating immune cells (TIICs) in specimens from 196 ESCC patients wh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hatogai, Ken, Kitano, Shigehisa, Fujii, Satoshi, Kojima, Takashi, Daiko, Hiroyuki, Nomura, Shogo, Yoshino, Takayuki, Ohtsu, Atsushi, Takiguchi, Yuichi, Doi, Toshihiko, Ochiai, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216939/ https://www.ncbi.nlm.nih.gov/pubmed/27322149 http://dx.doi.org/10.18632/oncotarget.10055

Ejemplares similares

Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma
por: Hatogai, Ken, et al.
Publicado: (2019)

Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma
por: Hatogai, Ken, et al.
Publicado: (2017)

Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer
por: Hatogai, Ken, et al.
Publicado: (2016)

Pathological tumor regression grade of metastatic tumors in lymph node predicts prognosis in esophageal cancer patients
por: Kadota, Tomohiro, et al.
Publicado: (2018)

Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303)
por: Kojima, Takashi, et al.
Publicado: (2022)

A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2016)

Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines
por: Fukuoka, Shota, et al.
Publicado: (2016)

Immunotherapy for Esophageal Squamous Cell Carcinoma
por: Kojima, Takashi, et al.
Publicado: (2017)

Special cancer microenvironment in human colonic cancer: Concept of cancer microenvironment formed by peritoneal invasion (CMPI) and implication of subperitoneal fibroblast in cancer progression
por: Kojima, Motohiro, et al.
Publicado: (2016)

Effect of food on the pharmacokinetics of TAS‐102 and its efficacy and safety in patients with advanced solid tumors
por: Yoshino, Takayuki, et al.
Publicado: (2016)

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites
por: Matsumoto, Hiroshi, et al.
Publicado: (2018)

Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2012)

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer
por: Kawazoe, Akihito, et al.
Publicado: (2015)

Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors
por: Ando, Yuichi, et al.
Publicado: (2014)

Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer
por: Doi, Toshihiko, et al.
Publicado: (2015)

Elastic Laminal Invasion in Colon Cancer: Diagnostic Utility and Histological Features
por: Kojima, Motohiro, et al.
Publicado: (2012)

Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma
por: Ito, Renma, et al.
Publicado: (2022)

Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2014)

A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2012)

Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer
por: Doi, Toshihiko, et al.
Publicado: (2013)

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
por: Mishima, Saori, et al.
Publicado: (2019)

Artificially Induced Epithelial-Mesenchymal Transition in Surgical Subjects: Its Implications in Clinical and Basic Cancer Research
por: Aoyagi, Kazuhiko, et al.
Publicado: (2011)

Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2015)

Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials
por: Nagatani, Yoshiaki, et al.
Publicado: (2016)

Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma
por: Mishima, Saori, et al.
Publicado: (2018)

Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by Chemoradiotherapy
por: Tanaka, Yosuke, et al.
Publicado: (2015)

Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports
por: Yoshino, Koji, et al.
Publicado: (2019)

Gene expression profiling to predict recurrence of advanced squamous cell carcinoma of the tongue: discovery and external validation
por: Enokida, Tomohiro, et al.
Publicado: (2017)

Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors
por: Murakami, Haruyasu, et al.
Publicado: (2012)

Clinical impact of surveillance for head and neck cancer in patients with esophageal squamous cell carcinoma
por: Morimoto, Hiroyuki, et al.
Publicado: (2017)

Identification of Makorin 1 as a novel SEREX antigen of esophageal squamous cell carcinoma
por: Shimada, Hideaki, et al.
Publicado: (2009)

Changes in the tumor microenvironment during lymphatic metastasis of lung squamous cell carcinoma
por: Ikemura, Shinnosuke, et al.
Publicado: (2017)

KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab
por: Bando, H, et al.
Publicado: (2011)

Phase I study of olaratumab in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2014)

Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies
por: Doi, Toshihiko, et al.
Publicado: (2020)

Thoracoscopic esophagectomy with three-field lymphadenectomy for thoracic esophageal cancer in a patient with a double aortic arch: a report of a case
por: Fujiwara, Hisashi, et al.
Publicado: (2019)

Clinicopathological Features of Early-Stage Esophageal Carcinosarcoma
por: Kubo, Kentaro, et al.
Publicado: (2022)

Human Subperitoneal Fibroblast and Cancer Cell Interaction Creates Microenvironment That Enhances Tumor Progression and Metastasis
por: Kojima, Motohiro, et al.
Publicado: (2014)

Spread of tumor microenvironment contributes to colonic obstruction through subperitoneal fibroblast activation in colon cancer
por: Yokota, Mitsuru, et al.
Publicado: (2015)

Immunohistochemical markers and the clinical course of adenosarcoma: a series of seven cases
por: Omi, Makiko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_maipoltid031f9efsumqbrsk3m